Project description DEENESFRITPL Novel biopsy procedure for targeted medicine diagnostics Traditional biopsy for cancer and other diagnosis includes tissue fixation in formalin and embedding in paraffin for subsequent microscopy analysis of the morphology. Advancements in biomedicine make possible the broad analysis of biomolecules (biomarkers) for evaluation of disease progression but require tissue samples to be fresh or frozen immediately after biopsy. Current biopsy devices do not provide this option. Sorek Medical Systems Ltd. has developed biopsy devices capable of automatically splitting tissue sample in two for simultaneous chemical fixation and freezing preservation. The current EU-funded phase of the project will test and validate devices in clinical applications. These devices could have broad application for not only cancer diagnosis but also pharmaceutical development of biomarker-targeting drugs for targeted and personalised medicine. Show the project objective Hide the project objective Objective Biopsy is a commonly used medical procedure for the diagnosis and characterization of cancer and other diseases. Traditionally, the tissue obtained is preserved by formalin fixation, embedded in paraffin, sectioned to thin tissue layers, and then analysed histologically under the microscope to evaluat overall tissue morphology. Current advancement in biomedicine makes it possible for greater use of molecular technologies. These technologies, allow for analysis of change in biomolecules (biomarkers) during cancer progression rather than tissue morphology alone. Laboratory analysis of biomarkers require tissue to be fresh (or fresh frozen) and rather not be preserved by formalin. In order to yield viable biomarker analysis tissue must be frozen as soon as possible because biomarkers are extremely sensitive to degradation. Current biopsy devices are not designed to meet these challenges of rapid freezing as a replacement to formalin fixation.We, at Sorek Medical Systems Ltd., a 16-year-old R&D company based in Israel, developed two biopsy devices that automatically split the tissue sample in two during biopsy acquisition. Our technology allows chemical standard formalin fixation for histology. Sorek’s devices will be used by radiologists and surgeons, and by pharmaceutical companies seeking the development of biomarker-targeting drugs with the goal of improving personalized medicine and improving early diagnosis for breast, lung, chest, prostate, and other organs’ cancer disease. Our CryoBiopsy Phase 2 project will allow us to test and validate our devices which will require € 2.8 million investment. Our financial forecast show that after five-year commercialization we will generate a cumulative revenues of €57 million and will create 20 positions which will include engineers, technicians and our own sales personnel Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesnatural sciencesphysical sciencesopticsmicroscopymedical and health sciencesclinical medicineoncologymedical and health scienceshealth sciencespersonalized medicinenatural sciencesbiological scienceshistology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator SOREK MEDICAL SYSTEMS LTD Net EU contribution € 1 603 000,00 Address Sha'ar yokneam apollo bldg 20692 Yokneam illit Israel See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 687 000,00
